Abstract 206P
Background
The key roles of the TP53 mutation in cancer have been well established. However, the different biological processes of urothelial carcinoma (UC) stratified by the TP53 mutation status has not yet been described. Mutational signatures can reveal biological processes underlying carcinogenesis.
Methods
Patients diagnosed with UC were enrolled in the study. Tumor tissue and matching blood were sequenced by next-generation sequencing (NGS) techniques with Acornmed panel with 808 cancer-related genes.
Results
A total of 139 patients were enrolled including 69 patients with TP53 mutation and 70 patients with TP53 wildtype. In TP53 mutation cohorts, the five most frequently mutated genes were TP53 (100%), KMT2D (55%), RB1 (29%), KMT2C (26%), and FAT1 (25%). For TP53 wildtype cohorts, the five most frequently mutated genes were KMT2D (43%), FGFR3 (30%), FAT1 (28%), BRD4 (26%), and KMT2C (25%). For top 20 gene, 4 frequently mutated genes were significant difference between TP53 mutation and TP53 wildtype cohorts, such as ERBB3, FGFR3, ERCC2, and STAG2, excluding the TP53 gene. C to T (C>T) substitutions and transitions were dominant mutation types in both cohorts (39.8% and 44.0%, 50% and 55%, respectively). APOBEC Cytidine Deaminase (Signature 2) were shown in both cohorts. Surprising, exposure to aristolochic acid (Signature 22) and defective DNA mismatch repair (Signature 6) were only existed in TP53 mutation cohorts, whereas spontaneous deamination of 5−methylcytosine (Signature 1) and defects in polymerase POLE (Signature 10) were only discovered in TP53 wildtype cohorts.
Conclusions
There were characterized the genomic differences and similarities, stratified by the TP53 status, which may reflect the UC patients with TP53 mutation harbored a specific biological process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
H.H. Liu, X.Y. Liang, L.B. Chen, Y. Zhang, H.N. Wang, F. Lou, S. Cao: Full/Part-time employment: Beijing Acornmed Biotechnology Co., Ltd.
Resources from the same session
61P - Clinical implication of BRCA mutation in breast cancer with central nervous system metastasis
Presenter: Jwa Hoon Kim
Session: e-Poster Display Session
62P - IGF axis in breast cancer recurrence and metastasis
Presenter: Hajara Akhter
Session: e-Poster Display Session
63P - Butterfly pea (<italic>Clitoria ternatea</italic> Linn.) flower extract prevents MCF-7 HER2-positive breast cancer cell metastasis in-vitro
Presenter: Azzahra Asysyifa
Session: e-Poster Display Session
64P - Pre-treatment absolute white blood cell profile count as metastatic predictive factors in invasive ductal carcinoma breast cancer
Presenter: Wikania I Gede
Session: e-Poster Display Session
65P - The new mouse anti-nNav1.5 monoclonal antibody
Presenter: Nur Aishah Sharudin
Session: e-Poster Display Session
66P - The TILs near solid structures is a potential prognostic factor of distant metastases in the luminal HER2-negative breast cancer
Presenter: Vladimir Alifanov
Session: e-Poster Display Session
73P - Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study
Presenter: Kyaw Thein
Session: e-Poster Display Session
74P - Comprehensive transcriptome analysis of endoplasmic reticulum stress in osteosarcomas
Presenter: Yoshiyuki Suehara
Session: e-Poster Display Session
75P - The evaluation of selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Presenter: Leo Yamada
Session: e-Poster Display Session
76P - Targeted tumour photoImmunotherapy against triple-negative breast cancer therapy
Presenter: Vivek Raju
Session: e-Poster Display Session